Video

Susan Melvin Hill on Supporting MPN Patients in Idaho

Susan Melvin Hill, patient advocate, discusses how she meets with and helps patients with myeloproliferative neoplasms (MPNs) in Idaho.

Susan Melvin Hill, patient advocate, discusses how she meets with and helps patients with myeloproliferative neoplasms (MPNs) in Idaho. Hill was named one of our 2015 MPN Heroes in the category of Commitment to the Broader MPN Community. Hill's journey began when she transitioned from myelofibrosis patient to dedicated patient advocate. In her dedication to help others with MPNs, Hill established Idaho’s first and only MPN support group. She currently mentors patients with MPNs in several states.

Hill continues to be involved in grassroots awareness activities. These include organizing the annual Rare Disease Day at the Idaho State Capitol, working to include MPN educational materials in the Leukemia & Lymphoma Society’s annual Light the Night Walk, supporting MPN Awareness Day with Governor’s Proclamations, and providing feedback on educational and patient advocacy materials for MPN publications. When she is not supporting MPN activities, Hill somehow finds the time to knit blankets for babies in the neonatal intensive care unit of her local hospital.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of man with text.
Dr. Breelyn Wilky explains how vague symptoms and testing challenges delay GIST diagnoses
Mark Daniels, an 83-year-old veteran and former fighter pilot, was shocked by his lymphoma diagnosis because he maintained exceptional physical fitness.
Image of man with text.
Image of women, with text.
Image of Dr. with text.
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Image of man with text.
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.